Abstract
Over 100 senior researchers and managers from academic and industrial research organisations attended this 2-day annual international discovery summit on antibacterial R&D. A number of firms, particularly biotechnology firms, presented compounds that are advancing through clinical development. In addition, areas for basic research and development included metallo-β-lactamases, ribosomal structural studies and phage-selected targets were described.